The good, the bad and lots of just plain old ugly: The Q1 numbers are in
Anyone expecting much upbeat news for biotech in Q1 of this year was in for a sore disappointment.
Our numbers czar, DealForma’s Chris Dokomajilar, crunched the stats for the first 3 months of the year and found plenty of downdrafts all around, with just a couple of silver linings to look at.
Biotech IPOs, as you might expect in a savage bear market, have largely evaporated from the scene — though some have made the leap with some early planning. SPACs, briefly the belle of the Wall Street ball, flared with fast cash and burned out, as you can see in the chart below.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.